Stock ESPR ESPERION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

MarketScreener Strategies Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Real-time Estimate Cboe BZX
Other stock markets
 12:07:45 2024-06-03 pm EDT 		5-day change 1st Jan Change
2.205 USD +2.08% Intraday chart for Esperion Therapeutics, Inc. +5.24% -26.09%
May. 22 Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events CI
May. 20 Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise MT

MarketScreener Strategies

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ESPR Stock
  4. News Esperion Therapeutics, Inc.
  5. MarketScreener Strategies